Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | B7-H3.CD28Z.CAR-T cells |
| Synonyms | |
| Therapy Description |
B7-H3.CD28Z.CAR-T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD276 (B7-H3) linked to a CD28 costimulatory domain, which potentially inhibit tumor growth (PMID: 30655315). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| B7-H3.CD28Z.CAR-T cells | B7H3.CD28Z CAR T-cells | CD276 Immune Cell Therapy 11 | B7-H3.CD28Z.CAR-T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD276 (B7-H3) linked to a CD28 costimulatory domain, which potentially inhibit tumor growth (PMID: 30655315). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07358260 | Phase I | B7-H3.CD28Z.CAR-T cells Cyclophosphamide + Fludarabine | B7-H3.CD28Z.CART in Solid Tumors | Not yet recruiting | USA | 0 |